Cargando…

Tolerability of Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes: Results from 6 Phase III Studies

BACKGROUND: Oral antihyperglycemic drugs used to treat type 2 diabetes mellitus (T2DM) vary in safety and tolerability. Treatment-related hypoglycemia and weight gain can exacerbate underlying disease. OBJECTIVES: To evaluate the tolerability of saxagliptin using data from phase III clinical trials....

Descripción completa

Detalles Bibliográficos
Autor principal:	Davidson, Jaime A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437547/ https://www.ncbi.nlm.nih.gov/pubmed/24456313 http://dx.doi.org/10.18553/jmcp.2014.20.2.120

Ejemplares similares

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar, Chetan S, et al.
Publicado: (2013)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Liu, Hao, et al.
Publicado: (2016)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
por: Li, Chun-Jun, et al.
Publicado: (2014)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
por: Konya, Hiroyuki, et al.
Publicado: (2014)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
por: Sharma, Morali D
Publicado: (2010)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
por: Elgart, Jorge F, et al.
Publicado: (2013)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz, Baptist
Publicado: (2010)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
por: Perl, Shira, et al.
Publicado: (2016)

The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study
por: Balkau, Beverley, et al.
Publicado: (2017)

Improving access to shared decision-making for Hispanics/Latinos with inadequately controlled type 2 diabetes mellitus
por: Davidson, Jaime A, et al.
Publicado: (2015)

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
por: Kim, Youngsook, et al.
Publicado: (2022)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu, Huan, et al.
Publicado: (2017)

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
por: Farr, Amanda M, et al.
Publicado: (2016)

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Men, Peng, et al.
Publicado: (2018)

Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study
por: Kajikawa, Masato, et al.
Publicado: (2019)

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
por: Saine, M Elle, et al.
Publicado: (2015)

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas
por: Hsieh, Sheng-Hwu, et al.
Publicado: (2010)

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
por: Sjöstrand, Mikaela, et al.
Publicado: (2017)

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial
por: Lu, Chieh‐Hsiang, et al.
Publicado: (2015)

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
por: Toth, Peter P
Publicado: (2014)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_i32lms9duvfjcsj575ns5bhf39